
    
      There will be 2 cohorts with enrollment in 2 parts. Participants will be treated on Day 1 of
      each 21-day cycle (every 3 weeks) with U3-1402 5.6 mg/kg intravenous (IV). The estimated
      treatment period is approximately 8 months and the follow-up period is approximately 4
      months.
    
  